Abstract
Checkpoint kinase 2 (Chk2) is a tumour suppressor and signal transducer in genome integrity checkpoints that coordinate cell-cycle progression with DNA repair or cell death in response to DNA damage. Defects of Chk2 occur in subsets of diverse sporadic malignancies and predispose to several types of hereditary carcinomas. However, the status of Chk2 in tumours of the urinary bladder remains unknown. Here, we report that among 58 advanced (grade T2–T4) human bladder carcinomas, immunohistochemical analysis revealed tumour-specific reduction or lack of Chk2 protein in 6 (10.3%) cases. Genetic analysis of the latter subset showed that a Chk2-negative carcinoma #668 harboured a truncating mutation 1100delC, in one Chk2 allele and loss of the corresponding second allele. The 1100delC mutation was also found in the germ line of this patient. Sequencing of TP53 in tumour #668 identified two missense mutations. Furthermore, the vast majority of the tumours showed ‘unscheduled’ activatory phosphorylation on Thr68 of Chk2 in the absence of any DNA-damaging treatment. Our results indicate that the otherwise dormant DNA damage signal transducer Chk2 is aberrantly and constitutively activated in invasive urinary bladder carcinomas, and that such likely proapoptotic checkpoint signalling can be disabled by inactivation of Chk2 and/or p53 tumour suppressors in subsets of these tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham RT . (2001). Genes Dev., 15, 2177–2196.
Ahn JY, Li X, Davis HL and Canman CE . (2002). Biol. Chem., 277, 19389–19395.
Ahn JY, Schwarz JK, Piwnica-Worms H and Canman CE . (2000). Cancer Res., 60, 5934–5936.
Bartek J, Falck J and Lukas J . (2001). Nat. Rev. Mol. Cell. Biol., 2, 877–886.
Bartek J and Lukas J . (2001). Curr Opin. Cell Biol., 13, 738–747.
Bartek J and Lukas J . (2003). Cancer Cell, 3, 421–429.
Bartkova J, Falck J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J and Bartek J . (2001). Oncogene, 20, 5897–5902.
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE and Haber DA . (1999). Science, 286, 2528–2531.
Chehab NH, Malikzay A, Appel M and Halazonetis TD . (2000). Genes Dev., 14, 278–288.
Craig A, Scott M, Burch L, Smith G, Ball K and Hupp T . (2003). EMBO Rep., 4, 787–792.
D'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter NP and Jackson SP . (2003). Nature, 426, 194–198.
DiTullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J and Halazonetis TD . (2002). Nat. Cell Biol., 4, 998–1002.
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN and Liu W . (2003). Am. J. Hum. Genet., 72, 270–280.
Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G and Bartek J . (2001). Oncogene, 20, 5503–5510.
Grønbæk K, Worm J, Ralfkier E, Ahrenkiel V, Hokland P and Guldberg P . (2002). Blood, 100, 1430–1437.
Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V and Zeuthen J . (1997). Hum. Mutat., 9, 348–355.
Hangaishi A, Ogawa S, Qiao Y, Wang L, Hosoya N, Yuji K, Imai Y, Takeuchi K, Miyawaki S and Hirai H . (2002). Blood, 99, 3075–3077.
Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y and Takahshi T . (2000). Cancer Res., 60, 4689–4692.
Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, de Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ and Mak TW . (2002). Mol. Cell. Biol., 22, 6521–6532.
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW . (2000). Science, 287, 1824–1827.
Hoeijmakers JH . (2001). Nature, 411, 366–374.
Hofman W-K, Miller CV, Tsukasaki T, Tavor S, Ikezoe T, Hoelzer D, Takeuchi S and Koeffler HP . (2001). Leukemia Res., 25, 333–338.
Kastan MB and Lim DS . (2000). Nat. Rev. Mol. Cell. Biol., 1, 179–186.
Khanna KK and Jackson SP . (2001). Nat. Genet., 27, 247–254.
Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E and Haber DA . (2001). Cancer Res., 61, 8062–8067.
Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J and Bartek J . (2001). Cancer Res., 61, 4990–4993.
Lukas C, Falck J, Bartkova J, Bartek J and Lukas J . (2003). Nat. Cell Biol., 421, 952–960.
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N and Stratton MR . (2002). Nat. Genet., 31, 55–59.
Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ and Takahashi T . (2001). Cancer Res., 61, 5362–5365.
Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K and Elledge SJ . (2000). Proc. Natl. Acad. Sci. USA, 97, 10389–10394.
Melchionna R, Chen XB, Blasina A and McGowan CH . (2000). Nat. Cell Biol., 2, 762–765.
Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S and Koeffler HP . (2002). Genes Chromosomes Cancer, 33, 17–21.
Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy JA, Evans DJ, Farrell PJ, Gusterson B, Gasco M and Crook T . (2002). Br. J. Cancer, 86, 756–760.
Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR and Rahman N . (2003). Am. J. Hum. Genet., 72, 1023–1028.
Seppälä EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MA, Tammela TLJ and Schleutker J . (2003). Br. J. Cancer, 89, 1966–1970.
Shieh SY, Ahn J, Tamai K, Taya Y and Prives C . (2000). Genes Dev., 14, 289–300.
Shiloh Y . (2003). Nat. Rev. Cancer, 3, 155–168.
Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS and Eeles RA . (2002a). Br. J. Cancer, 87, 1445–1448.
Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J and Eeles RA . (2002b). Hum. Mutat., 19, 173–177.
Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M and Crook T . (2002). Oncogene, 21, 1316–1324.
Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K and Motoyama N . (2002). EMBO J., 21, 5195–5205.
Takai H, Smogorzewska A and de Lange T . (2003). Curr. Biol., 13, 1549–1556.
Tavor S, Takeuchi S, Tsukasaki K, Miller CW, Hofmann WK, Ikezoe T, Said JW and Koeffler HP . (2001). Leukemia Lymphoma, 42, 517–520.
Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman JG, Puig X, Camacho E, Sanchez M, Nayach I, Lopez-Guillermo A, Fernandez PL, Colomer D, Hernandez L and Campo E . (2002). Blood, 100, 4602–4608.
Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP and Nevanlinna H . (2002). Am. J. Hum. Genet., 71, 432–438.
Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K and Nevanlinna H . (2001). Cancer Res., 61, 5718–5722.
Xu X, Tsvetkov L and Stern D . (2002). Mol. Cell. Biol., 22, 4419–4432.
Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF and Sherr CJ . (2003). Proc. Natl. Acad. Sci. USA, 100, 15930–15935.
Acknowledgements
We thank Mie Madsen, Hanne Steen, Inge Lis Thorsen and Bente Pylich for excellent technical assistance, and the Danish Cancer Society, the European Commission, The John and Birthe Meyer Foundation and the University of Aarhus for generous grant support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bartkova, J., Guldberg, P., Grønbæk, K. et al. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23, 8545–8551 (2004). https://doi.org/10.1038/sj.onc.1207878
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207878
Keywords
This article is cited by
-
The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer
Oncogene (2021)
-
53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway
Journal of Cancer Research and Clinical Oncology (2017)
-
CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
Oncogene (2012)
-
Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma
Nature Communications (2011)
-
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations
Breast Cancer Research and Treatment (2011)
